Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections
The revenues generated from these GLP-1 Agonists have been determined through annual reports and secondary sources (including paid databases) The products were mapped according to the market segments
The properly reconstituted solution should be clear and colorless
Unlike FDA-approved GLP-1 receptor agonists such as semaglutide or tirzepatide, these products are regulated as dietary supplements, not medications
Lancet 390 , 16641675 (2017)
The global GLP-1 receptor agonist market is rapidly expanding due to the rising prevalence of type 2 diabetes and obesity, which have become major public health concerns
